hearing health

Through more than 115 years, our company has developed hearing health and from this platform, we have taken new steps into the broader area of audio.

  • oticon_relaxed_man_on_bicycle_adobestock_105748270

    Interim Report 2022

    In the first half-year of 2022, the Demant Group delivered revenue growth of 9% due to strong performances by Diagnostics and Hearing Aids and gained market share in a Hearing Aids market that grew less than expected. Outlook for 2022 has been adjusted. Read the company announcement and the Interim Report 2022 here. You will find a link to the recorded webcast and the presentation here.

  • acquisition-of-shengwang

    Demant completes full acquisition of ShengWang

    On Tuesday 14 June 2022, Demant announced the acquisition of the remaining 80% of the shares in ShengWang, thereby taking full ownership of the leading network of hearing aid clinics in China. The investment represents a significant strategic transaction in Demant’s continuous journey within hearing healthcare. Read the company announcement here. 
  • oticon-medical-logo

    Demant intends to divest its Hearing Implants business

    Demant has negotiated an agreement with the intention to divest its Hearing Implants business, Oticon Medical, to Cochlear. The contemplated transaction follows a review of strategic options for the business area, including how to ensure the best lifelong support of existing patients - read the announcement. You will find a link to the recorded webcast and the presentation here.  

Total number of employees: about 20,000
Revenue in 2021: 18,418 MDKK
Operating profit in 2021: DKK 3,386 million
Presence: 130 countries
Employee gender distribution: 62% women and 38% men
CO2 emission reductions by 2030: minimum 50%
William Demant Foundation’s donations: DKK 124.1 million

  • Revenue
  • 27%
  • 2021: DKK 18,418 million
  • 2020: DKK 14,469 million
  • Operating profit (EBIT)
  • 158%
  • 2021: DKK 3,386 million
  • 2020: DKK 1,313 million